Providers: We’re here to help
Our partnership with our members’ healthcare providers is essential to ensure that we continue to deliver best in class pharmacy care to our members. We work closely with providers to deliver appropriate care management designed to lower net costs while maximizing health outcomes. The overall result: happier and healthier patients!
Member Services: 1.877.241.7123 / TDD 1.888.907.0020
Pharmacy Help Desk Assistance: 1.888.907.0050
Prior Auths/DUR: 1.888.723.6001
On June 28, 2016, FDA approved Gilead’s new drug, Epclusa, to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.read more
On January 28, 2016, Food and Drug Administration (FDA) has approved Merck and Co. manufactured Zepatier, a new oral treatment for adult patients with Chronic Hepatitis C (HCV) virus genotype 1 and 4 infections. Zepatier is a once a day fixed-dose oral combination...read more
What are PCSK9 Inhibitors? The Food and Drug Administration recently approved two products in a new class of cholesterol-lowering drugs known as PCSK9 Inhibitors. This class of drugs reduces the amount of low-density lipoprotein cholesterol (LDL-C), or “bad...read more